NCT00589472 - Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions

Prostate AdenocarcinomaStage I Prostate CancerStage IIA Prostate CancerStage IIB Prostate CancerStage III Prostate Cancer

Interventions

DRUG

Bicalutamide

Given PO

DRUG

Goserelin Acetate

Given SC

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Leuprolide Acetate

Given IM

PROCEDURE

Therapeutic Conventional Surgery

Undergo radical prostatectomy

DRUG

Vorinostat

Given PO

Trial Locations (15)

10065

Memorial Sloan-Kettering Cancer Center, New York

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

27710

Duke University Medical Center, Durham

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

48201

Wayne State University/Karmanos Cancer Institute, Detroit

53792

University of Wisconsin Hospital and Clinics, Madison

55905

Mayo Clinic, Rochester

60637

University of Chicago Comprehensive Cancer Center, Chicago

77030

M D Anderson Cancer Center, Houston

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

94143

UCSF Medical Center-Parnassus, San Francisco

97239

Oregon Health and Science University, Portland

98195

University of Washington Medical Center, Seattle

02115

Dana-Farber Cancer Institute, Boston

07103

UMDNJ - New Jersey Medical School, Newark

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH